FDA’s Promising New Framework for Rare Genetic Diseases

Partner Maarika Kimbrell co-authored an article in JAMA Health Forum, alongside former US Food and Drug Administration (FDA) Commissioner Scott Gottlieb, examining the FDA’s draft framework for individualized gene and RNA therapies for rare genetic diseases and its implications for regulatory strategy and compliance.

Read the full JAMA Health Forum article >>
Subscription may be required.